Last reviewed · How we verify
Acute graft-versus-host disease
Approved treatments
- Jakafi · Incyte Corp
Clinical guidelines
- FDA label — prophylactic
ORENCIA is indicated for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute graft-versus-host disease patent landscape — cliff calendar, originator estates, attackable patents
- Acute graft-versus-host disease treatment landscape brief
- Acute graft-versus-host disease treatment updates RSS
Frequently asked questions about Acute graft-versus-host disease
What drugs treat Acute graft-versus-host disease?
Tracked treatments include Jakafi.
What is the treatment for Acute graft-versus-host disease?
Standard treatment for Acute graft-versus-host disease includes Jakafi. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Acute graft-versus-host disease?
FDA label publishes guidelines for Acute graft-versus-host disease. 1 guideline references tracked.
Related
- Treatment landscape: Acute graft-versus-host disease patent cliff · Acute graft-versus-host disease CI report
- Treatment: Jakafi · Incyte Corp
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing